1. 183P COMMANDER-001: Initial safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors. (December 2022) Authors: Moser, J.; Pelster, M.; Jimeno, A.; Park, J.C.; Iams, W.T.; Wise-Draper, T.; Jennings, ; Miselis, N.R.; Ji, R.R.; Loughhead, S.M.; Zwirtes, R.; Warren, M.; Sharei, A.; Bernstein, H.; Gordon, M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. (December 2022) Authors: Csiki, I.; Glenn, J.; Boccia, R.; Chen, C.; Gordon, M.; Misleh, J.; Powderly, J.; Wainberg, Z.A.; Spira, A.; Klumpp, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. (September 2015) Authors: Disis, M.L.; Patel, M.; Pant, S.; Hamilton, E.P.; Lockhart, A.C.; Kelly, K.; Thaddeus-Beck, J.; Gordon, M.; Weiss, G.J.; Ejadi, S.; Taylor, M.H.; Chin, K.; Cuillerot, J.M.; Von Heydebreck, A.; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A bioinformatics tool for ensuring the backwards compatibility of Legionella pneumophila typing in the genomic era. (May 2017) Authors: Gordon, M.; Yakunin, E.; Valinsky, L.; Chalifa-Caspi, V.; Moran-Gilad, J. Journal: Clinical microbiology and infection Issue: Volume 23:Number 5(2017) Page Start: 306 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors. (December 2016) Authors: Jimeno, A.; Moore, K.; Gordon, M.; Chugh, R.; Diamond, J.; Aljumaily, R.; Stagg, R.; Dupont, J.; Smith, D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Abstract O-53: THE IMPORTANCE OF SIMULATION TO TEST THE ADEQUACY OF SYSTEMS, PROCESSES AND PATIENT SAFETY MEASURES IN A NEW PAEDIATRIC CRITICAL CARE UNIT. (June 2018) Authors: Lister, P.; Gordon, M.; Morgan, L. Journal: Pediatric critical care medicine Issue: Volume 19(2018)Supplement 1 6 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. An increasing number of convolutional neural networks for fracture recognition and classification in orthopaedics. (2021) Authors: Carmo, L. Oliveira e; Merkhof, A. van den; Olczak, J.; Gordon, M.; Jutte, P. C.; Jaarsma, R. L.; IJpma, F. F. A.; Doornberg, J. N.; Prijs, J. Journal: Bone & joint open Issue: Volume 2:Number 10(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress. (1st July 2021) Authors: Meyer, J.M.; Lee, E.; Celli, A.; Park, K.; Cho, R.; Lambert, W.; Pitchford, M.; Gordon, M.; Tsai, K.; Cleaver, J.; Arron, S.T.; Mauro, T.M. Journal: British journal of dermatology Issue: Volume 185:Number 1(2021) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress. (5th February 2021) Authors: Meyer, J.M.; Lee, E.; Celli, A.; Park, K.; Cho, R.; Lambert, W.; Pitchford, M.; Gordon, M.; Tsai, K.; Cleaver, J.; Arron, S.T.; Mauro, T.M. Journal: British journal of dermatology Issue: Volume 185:Number 1(2021) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. (December 2016) Authors: Janku, F.; George, S.; Razak, A.; Gordon, M.; Brooks, D.; Flynn, D.G.; Kaufman, M.; Pitman, J.; Smith, B.; Somaiah, N.; Gerstenberger, E.; Westwood, D.; Rosen, O. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗